Pharma Mar S.A. (PHM) - Cash Flow Conversion Efficiency
Based on the latest financial reports, Pharma Mar S.A. (PHM) has a cash flow conversion efficiency ratio of 0.133x as of December 2025. Cash flow conversion efficiency measures how effectively a company's net assets (equity) generate operating cash flow. It is calculated by dividing operating cash flow (€33.58 Million ≈ $39.26 Million USD) by net assets (€251.83 Million ≈ $294.42 Million USD). A higher ratio indicates that the company is more efficient at using its equity to generate cash flow from its core operations. Also see PHM company net worth for the company's overall valuation and market capitalisation.
Pharma Mar S.A. - Cash Flow Conversion Efficiency Trend (2002–2025)
This chart illustrates how Pharma Mar S.A.'s cash flow conversion efficiency has evolved over time, based on yearly financial data.
Pharma Mar S.A. Competitors by Cash Flow Conversion Efficiency
The table below lists competitors of Pharma Mar S.A. ranked by their cash flow conversion efficiency. Explore earnings quality score of Pharma Mar S.A. to measure how well operating cash flow supports reported net income.
| Company | Cash Flow Conversion Efficiency |
|---|---|
|
Tong Yang Industry Co Ltd
TW:1319
|
0.079x |
|
Hebei Hengshui Laobaigan Liquor Co Ltd
SHG:600559
|
-0.012x |
|
Jungfraubahn Holding AG
SW:JFN
|
0.045x |
|
Xiamen Kingdomway Group Co
SHE:002626
|
0.040x |
|
Changchun UP Optotech Co Ltd
SHE:002338
|
-0.016x |
|
Marqeta Inc
NASDAQ:MQ
|
88.289x |
|
Capital Southwest Corporation
NASDAQ:CSWC
|
-0.076x |
|
Global Blue Group Holding Ltd
NYSE:GB
|
0.190x |
Annual Cash Flow Conversion Efficiency for Pharma Mar S.A. (2002–2025)
The table below shows the annual cash flow conversion efficiency of Pharma Mar S.A. from 2002 to 2025. View PHM share price today for real-time trading data and today's change.
| Year | Net Assets | Operating Cash Flow | Cash Flow Conversion Efficiency | Change |
|---|---|---|---|---|
| 2025-12-31 | €251.83 Million ≈ $294.42 Million |
€53.13 Million ≈ $62.11 Million |
0.211x | +629.35% |
| 2024-12-31 | €208.36 Million ≈ $243.59 Million |
€6.03 Million ≈ $7.05 Million |
0.029x | +141.61% |
| 2023-12-31 | €193.44 Million ≈ $226.15 Million |
€-13.45 Million ≈ $-15.72 Million |
-0.070x | -140.44% |
| 2022-12-31 | €222.96 Million ≈ $260.66 Million |
€38.32 Million ≈ $44.80 Million |
0.172x | +19.09% |
| 2021-12-31 | €177.92 Million ≈ $208.00 Million |
€25.68 Million ≈ $30.02 Million |
0.144x | -94.69% |
| 2020-12-31 | €102.72 Million ≈ $120.09 Million |
€278.94 Million ≈ $326.11 Million |
2.716x | +177.46% |
| 2019-12-31 | €7.46 Million ≈ $8.72 Million |
€-26.14 Million ≈ $-30.56 Million |
-3.505x | -274.86% |
| 2018-12-31 | €17.47 Million ≈ $20.43 Million |
€-16.34 Million ≈ $-19.10 Million |
-0.935x | -1373.18% |
| 2017-12-31 | €22.98 Million ≈ $26.87 Million |
€-1.46 Million ≈ $-1.71 Million |
-0.063x | +63.41% |
| 2016-12-31 | €48.49 Million ≈ $56.70 Million |
€-8.41 Million ≈ $-9.84 Million |
-0.174x | -214.15% |
| 2015-12-31 | €73.04 Million ≈ $85.39 Million |
€11.10 Million ≈ $12.98 Million |
0.152x | -58.70% |
| 2014-12-31 | €60.07 Million ≈ $70.23 Million |
€22.11 Million ≈ $25.85 Million |
0.368x | +11.32% |
| 2013-12-31 | €49.44 Million ≈ $57.79 Million |
€16.34 Million ≈ $19.11 Million |
0.331x | +102.63% |
| 2012-12-31 | €38.73 Million ≈ $45.27 Million |
€6.32 Million ≈ $7.39 Million |
0.163x | +231.48% |
| 2011-12-31 | €34.50 Million ≈ $40.34 Million |
€-4.28 Million ≈ $-5.01 Million |
-0.124x | +80.24% |
| 2010-12-31 | €34.86 Million ≈ $40.76 Million |
€-21.90 Million ≈ $-25.60 Million |
-0.628x | -14.01% |
| 2009-12-31 | €41.14 Million ≈ $48.09 Million |
€-22.67 Million ≈ $-26.50 Million |
-0.551x | +23.75% |
| 2008-12-31 | €49.34 Million ≈ $57.69 Million |
€-35.66 Million ≈ $-41.69 Million |
-0.723x | -45.25% |
| 2007-12-31 | €98.81 Million ≈ $115.52 Million |
€-49.16 Million ≈ $-57.47 Million |
-0.497x | +4.99% |
| 2006-12-31 | €107.17 Million ≈ $125.30 Million |
€-56.11 Million ≈ $-65.60 Million |
-0.524x | -470.66% |
| 2005-12-31 | €360.04 Million ≈ $420.93 Million |
€-33.03 Million ≈ $-38.62 Million |
-0.092x | +80.98% |
| 2003-12-31 | €139.28 Million ≈ $162.83 Million |
€-67.18 Million ≈ $-78.54 Million |
-0.482x | -125.85% |
| 2002-12-31 | €166.90 Million ≈ $195.12 Million |
€-35.64 Million ≈ $-41.67 Million |
-0.214x | -- |
About Pharma Mar S.A.
Pharma Mar, S.A., a biopharmaceutical company, focuses on the research, development, production, and commercialization of bio-active principles for the use in oncology in Spain, Germany, Ireland, France, Switzerland, rest of the European Union, the United States, and internationally. It operates through Oncology and RNA Interference segments. The company offers Yondelis, a synthetic compound deri… Read more